Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
9.32
|
9.40
|
9.24
|
9.24
|
9.40
|
9.40
|
|
|
3 134.38
|
9.00
|
9.20
|
9.26
|
9.30
|
9.20
|
9.36
|
9.22
|
|
|
5 521.30
|
15.00
|
9.30
|
9.36
|
9.50
|
9.30
|
9.50
|
9.30
|
|
|
5 885.94
|
14.00
|
9.36
|
9.40
|
9.26
|
9.26
|
9.60
|
9.36
|
|
|
12 758.82
|
35.00
|
8.90
|
9.06
|
9.06
|
9.00
|
9.06
|
9.06
|
|
|
1 568.64
|
8.00
|
8.78
|
9.06
|
8.80
|
8.80
|
9.06
|
9.06
|
|
|
6 077.32
|
15.00
|
8.78
|
8.80
|
8.82
|
8.76
|
8.82
|
8.80
|
|
|
1 915.78
|
7.00
|
8.80
|
8.82
|
8.86
|
8.74
|
8.86
|
8.74
|
|
|
3 161.00
|
11.00
|
8.74
|
8.82
|
8.72
|
8.60
|
8.88
|
8.82
|
|
|
17 166.56
|
25.00
|
8.70
|
8.80
|
8.98
|
8.72
|
9.06
|
8.72
|
|
|
25 220.90
|
44.00
|
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase II (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase Ib (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).